Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …

Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of
their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts …

Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the
development of anticancer immunotherapy agents has thrived. The success of many …

Myeloid cells in tumor tissues constitute a dynamic immune population characterized by a
non-uniform phenotype and diverse functional activities. Both tumor-associated …

Mesenchymal stromal cells (MSCs) are currently being investigated for use in a wide variety
of clinical applications. For most of these applications, systemic delivery of the cells is …

Immunotherapy, specifically the introduction of immune checkpoint inhibitors, has
transformed the treatment of cancer, enabling long-term tumour control even in individuals …

Tumors are composed of different types of cancer cells that contribute to tumor
heterogeneity. Among these populations of cells, cancer stem cells (CSCs) play an …

The development of mesenchymal stem cells (MSCs) as cell-based drug delivery vectors for
numerous clinical indications, including cancer, has significant promise. However, a …

Cancer cells undergo unlimited progression and survival owing to activation of oncogenes.
However, support of the tumor microenvironment is essential to the formation of clinically …